CN102316892B - 心肌营养素-1用于治疗代谢病的用途 - Google Patents

心肌营养素-1用于治疗代谢病的用途 Download PDF

Info

Publication number
CN102316892B
CN102316892B CN201080009256.9A CN201080009256A CN102316892B CN 102316892 B CN102316892 B CN 102316892B CN 201080009256 A CN201080009256 A CN 201080009256A CN 102316892 B CN102316892 B CN 102316892B
Authority
CN
China
Prior art keywords
insulin
rct
treatment
mice
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080009256.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102316892A (zh
Inventor
赫苏斯·玛丽亚·普列托·巴尔图埃纳
马蒂尔德·布斯托斯·德·阿凡霍
玛丽亚·赫苏斯·莫雷尼奥·阿里阿加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Universidad de Navarra
Original Assignee
Proyecto de Biomedicina CIMA SL
Universidad de Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL, Universidad de Navarra filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN102316892A publication Critical patent/CN102316892A/zh
Application granted granted Critical
Publication of CN102316892B publication Critical patent/CN102316892B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080009256.9A 2009-02-12 2010-02-10 心肌营养素-1用于治疗代谢病的用途 Expired - Fee Related CN102316892B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200900396 2009-02-12
ES200900396 2009-02-12
PCT/ES2010/070072 WO2010092218A2 (es) 2009-02-12 2010-02-10 Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas

Publications (2)

Publication Number Publication Date
CN102316892A CN102316892A (zh) 2012-01-11
CN102316892B true CN102316892B (zh) 2014-06-04

Family

ID=42562119

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080009256.9A Expired - Fee Related CN102316892B (zh) 2009-02-12 2010-02-10 心肌营养素-1用于治疗代谢病的用途

Country Status (11)

Country Link
US (1) US20110293562A1 (https=)
EP (1) EP2397152B1 (https=)
JP (1) JP2012517459A (https=)
CN (1) CN102316892B (https=)
AU (1) AU2010212794A1 (https=)
BR (1) BRPI1008415A2 (https=)
CA (1) CA2750074A1 (https=)
ES (1) ES2493618T3 (https=)
MX (1) MX2011008562A (https=)
RU (1) RU2011137413A (https=)
WO (1) WO2010092218A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
CN106255748B (zh) * 2014-02-24 2025-10-28 释放能量医药股份有限公司 诱导人褐色脂肪细胞祖细胞分化的方法和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE69916031T2 (de) 1998-01-29 2005-02-17 Poly-Med Inc. Asorbierbare mikropartikel
ATE251465T1 (de) 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP2005534345A (ja) * 2002-07-29 2005-11-17 エス セル インターナショナル ピーティーイー リミテッド インスリン陽性、グルコース応答性細胞の分化のための多段階方法
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
WO2006097526A1 (en) * 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
BRPI0707869A2 (pt) 2006-02-15 2011-05-10 Sanofi Aventis ariltienopirimidinonas substituÍdas com azaciclil, processo para a sua preparaÇço e seus usos como medicamentos

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Effects of Cardiotrophin on Adipocytes";Sanjin Zvonic et al.,;《The Journal of Biological Chemistry》;20040831;第279卷(第46期);第47572页-第47579页 *
"gp130 receptor ligands as potential therapeutic targets for obesity";Mark A.Febbraio;《Journal of Clinical Investigation》;20070402;第117卷(第4期);第841页-第849页 *
B.Macros-Gomez et al.,."Obesity, inflammation and insulin resistance:role of gp 130 receptor ligands".《An Sist Sanit Navar》.2008,第31卷(第2期),第113页-第123页. *

Also Published As

Publication number Publication date
ES2493618T3 (es) 2014-09-12
JP2012517459A (ja) 2012-08-02
CN102316892A (zh) 2012-01-11
RU2011137413A (ru) 2013-03-20
EP2397152B1 (en) 2014-05-28
MX2011008562A (es) 2011-09-09
WO2010092218A2 (es) 2010-08-19
CA2750074A1 (en) 2010-08-19
EP2397152A2 (en) 2011-12-21
BRPI1008415A2 (pt) 2018-02-27
AU2010212794A1 (en) 2011-08-11
WO2010092218A3 (es) 2010-11-18
US20110293562A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
JP5814525B2 (ja) 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
CN103249427A (zh) 速效胰岛素联合长效胰岛素
KR20160075794A (ko) 질환 및 질병 치료용 칼시토닌 모방체
EP3892289A1 (en) Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis
CN105188736A (zh) 胰岛素给药方案
RU2670106C2 (ru) Фармацевтическая композиция
CN102316892B (zh) 心肌营养素-1用于治疗代谢病的用途
CN110628723A (zh) 基因修饰MSCs治疗2型糖尿病
US20240139288A1 (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
ES2320139T3 (es) Uso de t-cadherina soluble para el tratamiento de trastornos metabolicos.
US20140038887A1 (en) Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
CN110799527A (zh) 用于治疗疾病和病症的降钙素模拟物
CA2556923A1 (en) Methods of treating obesity or diabetes using nt-4/5
US10052362B2 (en) Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
Chen et al. An overview of hypoglycemic biological drugs
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
CN100556455C (zh) 一种用于预防和治疗i型糖尿病的药物复合物及其应用
CN116018156A (zh) 使用人类胰淀素类似物多肽对1型糖尿病患者提供卓越的血糖控制
WO2024249549A2 (en) Therapeutic uses of adipose-secreted signaling protein (adissp)
CN101711862B (zh) 一种炎症性疾病相关的药物靶点及其应用
CN103585629B (zh) 一种防治胰岛素抵抗及其相关疾病的靶标
KR20220110506A (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법
US20180099031A1 (en) Diabetes treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: UNIVERSIDAD DE NAVARRA

Free format text: FORMER OWNER: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA S A

Effective date: 20130320

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130320

Address after: Navarra Spain

Applicant after: Proyecto Biomedicina Cima Sl

Applicant after: UNIV DE NAVARRA

Address before: Navarra Spain

Applicant before: Proyecto Biomedicina Cima Sl

Applicant before: Instituto Cientifico Y Tecnologico De Navarra S A

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140604

Termination date: 20150210

EXPY Termination of patent right or utility model